Clinical target promiscuity: lessons from ras molecular trials.

Abstract excerpt

Mutated ras has been identified in approximately 30% of human tumors, and dysregulation of ras function and signal transduction pathways is a critical step in tumorigenesis. Herein, we review the early data that supports the concept that the intrinsic radiosensitivity of tumor cells can be altered by oncogenic ras expression and that this impacts the PI3K-dependent signaling cascade. This ras-induced...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomarkers, Tumor
• Share to Clinical Trials as Topic
• Share to Enzyme Inhibitors